Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort

Andrea Casadei-Gardinia Leonardo Solainib, c Laura Riggi a Eleonora Molinaroa Vincenzo Dadduziod Mario Domenico Rizzatod Antonio Pellinod Luca Faloppie Giorgia Marisif Paola Ulivif Matteo Canalef Giulia Orsi a Giulia Rovestia Kalliopi Andrikou a Andrea Spallanzani a Fabio Gelsomino a Francesco Giuseppe Foschig Fabio Contig Alessandro Cucchetti b, c Giorgio Ercolani b, c Paola Biasond Sara Lonardijd Stefano Cascinua Mario Scartozzid

a Department of Oncology and Hematology, Division of Oncology, University Hospital Modena, Modena, Italy; b Department of Medical and Surgical Sciences – DIMEC, Alma Mater Studiorum – University of Bologna, Bologna, Italy; c General and Oncology Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy; d Unit of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; e Medical Oncology, University Hospital of Cagliari, Cagliari, Italy; f Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; g Department of Internal Medicine, Degli Infermi Hospital, Faenza, Italy

Keywords
α-Fetoprotein · Lactate dehydrogenase · Neutrophil-to-lymphocyte ratio · Platelet-to-lymphocyte ratio · Systemic inflammatory index

Abstract
Background and Aims: The aim of the present study is to evaluate a new index influenced by the balance between the immune system, α-fetoprotein (AFP), and lactate dehydrogenase (LDH) (RAPID index) as a prognostic factor in patients treated with sorafenib. Methods: This study was conducted on a training cohort of 159 hepatocellular carcinoma (HCC) patients and a validation cohort of 68 HCC patients treated with sorafenib. The RAPID index was calculated as neutrophil/lymphocyte count × LDH × AFP. Results: In the training cohort, the median overall survival (OS) was 23.2 months (95% CI 11–25) and 12.1 months (95% CI 9–15) for patients with a low (≤ 3,226) and high (> 3,226) RAPID index, respectively (ref. < 3,226, HR = 0.56, 95% CI 0.35–0.88, p = 0.017). Following adjustment for clinical covariates, multivariate analysis confirmed the RAPID index ≤ 3,226 versus > 3,226 (HR = 0.37, 95% CI 0.18–0.74, p = 0.0054) as an
independent prognostic factor for OS. In the validation cohort, the median OS was 26.9 months (95% CI 17.6–26.9) and 7.0 months (95% CI 6.2–9.2) for patients with a low (≤ 3,226) and high (> 3,226) RAPID index, respectively (ref. < 3,226, HR = 0.19, 95% CI 0.10–0.36, p < 0.0001). Performing the same multivariate analysis of the training cohort (AFP, Eastern Cooperative Oncology Group, aspartate aminotransferase, neutrophil, platelet, systemic inflammatory index and RAPID index), the RAPID index < 3,226 versus > 3,226 (HR = 3.86, 95% CI 1.45–10.29, p = 0.007) was found to be an independent prognostic factor for predicting OS. **Conclusion:** The low cost, easy assessment, and reproducibility of a full blood count make the RAPID index a promising tool for assessing HCC prognosis in future clinical practice.

Introduction

Based on the results of two phase III studies (SHARP study and Asia-Pacific trial), sorafenib has become the standard first-line therapy for unresectable hepatocellular carcinoma (HCC) [1, 2]. However, the ideal patient who could benefit from sorafenib has yet to be defined and several investigators have been looking for predictive factors to improve patients’ selection [3].

α-Fetoprotein (AFP) is the most common serum marker assessed in clinical practice for the diagnosis of HCC, but it is characterized by low sensitivity and specificity. Indeed, several patients with advanced HCC could exhibit normal values of AFP; on the other hand, benign conditions, like liver cirrhosis, may cause an increase in AFP levels [4].

Lactate dehydrogenase (LDH), which catalyzes the reaction to convert pyruvate to lactate in an anaerobic setting, was also investigated as a potential marker of HCC [5, 6]. It has been found that LDH serum levels are a surrogate marker of tumor hypoxia, neo-angiogenesis, metastasis development, and poor prognosis in several malignancies [7].

Finally, in the last decade, the role of systemic inflammation has gained more importance in different kinds of neoplasias [8]. Inflammatory microenvironment is one of the factors responsible for oncogenesis, angiogenesis, and disease progression. Neutrophil-to-lymphocyte ratio (NLR) in peripheral blood has been found to have an impact on survival in some solid malignancies [9–11]. In addition, the neutrophilic infiltration in peritumoral stroma can promote angiogenesis and its presence in intratumoral tissue can enhance autophagic activity. This favors tumor growth and is associated with poor prognosis [12]. In contrast, an elevated number of lymphocytes in the tumor tissue may be associated with a better prognosis [13]. Besides, lymphopenia may be an expression of deficit of the immune system mediated by a shortage of CD4+ T-helper and cytotoxic CD8+ cells [14]. On the other hand, neutrophils produce a variety of cytokines, such as vascular endothelial growth factor (VEGF), tumor necrosis factor, angiopoietin-1, and metalloproteinase-9, which can promote carcinogenesis [15]. Moreover, elevated NLR is associated with increased levels of IL-17, which seems to promote tumor invasion and HCC cell growth [16].

In this context, the aim of the present study is to evaluate a new index influenced by the balance between the immune system, AFP, and LDH as a prognostic factor in HCC patients treated with sorafenib. This new factor is named RAPID index.

Patients and Methods

**Patients and Treatment**

This multicentric Italian study was conducted on a training cohort of 159 HCC patients consecutively treated at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori from 2007 to 2015. A prospective validation cohort of 68 HCC patients was consecutively recruited by the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori and Istituto Oncologico Veneto-IRCCS from 2015 to 2018.
Table 1. Patient characteristics in the training and validation cohort

|                         | Training cohort (n = 159) | Validation cohort (n = 68) | p value |
|-------------------------|---------------------------|---------------------------|---------|
| Median age, years       | 70 (67–71)                | 64 (60–67)                | 0.03    |
| Gender                  |                           |                           |         |
| Male                    | 141 (88.7)                | 58 (85.3)                 | 0.51    |
| Female                  | 18 (11.3)                 | 10 (14.7)                 |         |
| Etiology                |                           |                           |         |
| HCV                     | 74 (46.5)                 | 28 (41.2)                 |         |
| HBV                     | 38 (23.9)                 | 10 (14.7)                 |         |
| Others                  | 47 (29.6)                 | 30 (44.1)                 | 0.07    |
| Smoking habits           |                           |                           |         |
| Yes                     | 35 (22.0)                 | 16 (23.5)                 |         |
| No                      | 124 (78)                  | 52 (76.5)                 | 0.86    |
| Previous treatment      |                           |                           |         |
| None                    | 35 (22.0)                 | 16 (23.6)                 |         |
| Surgery                 | 28 (17.6)                 | 12 (17.6)                 |         |
| Radiofrequency          | 41 (25.7)                 | 17 (25.0)                 |         |
| Transarterial chemoembolization | 55 (34.8)     | 25 (33.8)                 | 0.99    |
| BCLC stage              |                           |                           |         |
| B                       | 23 (14.5)                 | 24 (35.3)                 |         |
| C                       | 133 (83.6)                | 44 (64.7)                 | 0.0005  |
| Unknow                  | 3 (1.9)                   | –                         |         |
| Child-Pugh              |                           |                           |         |
| A                       | 118 (74.2)                | 63 (92.)                  |         |
| B                       | 6 (3.8)                   | 5 (7.4%)                  | 0.47    |
| Unknow                  | 35 (22)                   | –                         |         |
| ECOG                    |                           |                           |         |
| 0                       | 65 (40.9)                 | 45 (66.2)                 |         |
| Others                  | 67 (42.1)                 | 18 (26.4)                 | 0.003   |
| Unknow                  | 27 (17)                   | 5 (7.4)                   |         |
| Extrahepatic disease    |                           |                           |         |
| No                      | 93 (58.5)                 | 40 (58.8)                 |         |
| Yes                     | 60 (37.7)                 | 28 (41.2)                 | 0.88    |
| Unknow                  | 6 (3.8)                   | –                         |         |
| Portal vein thrombosis  |                           |                           |         |
| No                      | 89 (56)                   | 42 (61.8)                 |         |
| Yes                     | 65 (40.9)                 | 26 (38.2)                 | 0.65    |
| Unknow                  | 5 (3.1)                   | –                         |         |
| α-Fetoprotein           |                           |                           |         |
| <400                    | 118 (74.%)                | 44 (64.7)                 |         |
| >400                    | 41 (25.8)                 | 24 (35.3)                 | 0.14    |
| Lactate dehydrogenase   |                           |                           | <0.0001 |
| Neutrophil              | 3.560 (3.359–3.900)       | 4.050 (3.523–4.647)       | 0.12    |
| Lymphocytes             | 1,300 (1,220–1,450)       | 1,455 (1,264–1,654)       | 0.50    |
| Neutrophil/lymphocyte ratio | <3 99 (62.3) | 36 (52.9) |         |
| >3                      | 60 (37.7)                 | 32 (47.1)                 | 0.23    |
| Systemic inflammatory index | <360 75 (47.2) | 24 (35.3) |         |
| >360                    | 83 (52.2)                 | 44 (64.7)                 | 0.10    |
| Unknow                  | 1 (0.6)                   | –                         |         |
| Platelet-to-lymphocyte ratio | <16 107 (67.3) | 39 (57.4) |         |
| >16                     | 51 (32.1)                 | 29 (42.6)                 | 0.09    |
| Unknow                  | 1 (0.6)                   | –                         |         |
| Aspartate aminotransferase | <34 19 (11.9) | 13 (19.1) |         |
| >34                     | 110 (69.2)                | 46 (67.7)                 | 0.21    |
| Unknow                  | 30 (18.9)                 | 9 (13.2)                  |         |
| RAPID index             |                           |                           |         |
| <3,226                  | 24 (15.1)                 | 24 (35.3)                 |         |
| >3,226                  | 135 (84.9)                | 44 (64.7)                 | 0.001   |

Figures in parentheses are ranges or percentages.
Patients with histologically or radiologically (according to the American Association for the Study of Liver Diseases 2005 guidelines) proven advanced- or intermediate-stage (refractory or unsuitable for locoregional therapies) HCC treated with sorafenib were eligible for our analysis. Patients who had received previous systemic therapies were excluded. Eligibility criteria were the same as those of Llovet's [1] pivotal study on sorafenib in HCC: Eastern Cooperative Oncology Group (ECOG) performance status score of \( \leq \) 2; Child-Pugh liver function class A; adequate hematologic function (platelet count, \( \geq 60 \times 10^9 \) /L; hemoglobin \( \geq 8.5 \) g/dL); and prothrombin time international normalized ratio \( \leq 2.3 \) or prothrombin time \( \leq 6 \) s above control, adequate hepatic function (albumin \( \geq 2.8 \) g/dL; total bilirubin \( \leq 3 \) mg/dL [51.3 \( \mu \)mol/L]; alanine aminotransferase and aspartate aminotransferase (AST) \( \leq 5 \) times the upper limit of the normal range); and adequate renal function (serum creatinine \( \leq 1.5 \) times the upper limit of the normal range).

All patients received sorafenib according to the standard schedule (400 mg bid continuously); dose reduction was applied as clinically indicated. Follow-up consisted of CT/MRI scan every 8 weeks or as clinically indicated. Tumor response was evaluated by modified Response Evaluation Criteria in Solid Tumors (mRECIST). Treatment with sorafenib was continued until disease progression, unacceptable toxicity or death.

The study protocol was reviewed and approved by the local Ethics Committee (CEIIAV: comitato etico IRST IRCCS AVR; study number IRST B041, protocol number 5482/v.1, intern code L3P1192). All patients provided written informed consent.

**Statistical Analysis**

The aim of this analysis was to examine the association between baseline RAPID index levels and overall survival (OS) in patients with HCC treated with sorafenib.

Baseline neutrophil and lymphocyte count, LDH, and AFP blood levels were retrieved the day before the start of the treatment.

The RAPID index was calculated as NLR × LDH × AFP. X-tile 3.6.1 software (Yale University, New Haven, CT, USA) was used to determine the cutoff value for baseline levels. Categorical variables were compared with Fisher's exact test.

OS was defined as the time interval between the first day of treatment until the day of death or last follow-up visit. OS were estimated by the Kaplan-Meier method and curves were compared by the log-rank test. Unadjusted and adjusted hazard ratios (HRs) by baseline characteristics (AFP, gender, etiology, ECOG performance status, AST, systemic immune-inflammation index, neutrophil) were calculated using the Cox proportional hazards model. The predictive value and the discrimination ability of the final model were assessed with the Harrell's concordance index (C-index).

MedCalc package (MedCalc® version 16.8.4) was used for statistical analysis.

**Fig. 1.** Overall survival in relation to the RAPID index in the training cohort.
Results

Patient Characteristics

Between June 2007 and August 2018, 159 patients with HCC treated with sorafenib were included in the training cohort. Median follow-up was 42.3 months (95% CI 35.0–55.0). Median OS was 13.1 months (95% CI 10.9–15.9).

Between March 2015 and June 2018, 68 patients with HCC treated with sorafenib were enrolled in the validation cohort. Median follow-up was 17.2 months (95% CI 13.3–20.7). Median OS was 12.9 months (95% CI 10.8–15.6). Patient characteristics are shown in Table 1.

Clinical Outcome in the Training Cohort

The RAPID index, analyzed as a continuous variable, was associated with OS (HR = 1.0003, 95% CI 1.0002–1.0004, \( p < 0.0001 \)). Median OS was 23.2 months (95% CI 11–25) and 12.1 months (95% CI 9–15) for patients with a low \((\leq 3,226)\) and high \((> 3,226)\) RAPID index, respectively (ref. <3,226, HR = 0.56, 95% CI 0.35–0.88, \( p = 0.017 \)) (Fig. 1; Table 2). The two groups of patients \((\leq \text{ and } > 3,226)\) were comparable for all the clinical characteristics investigated (Table 3).

At univariate analysis, the other parameters associated with prognosis were: ECOG (median OS was 16.3 months [95% CI 13.1–18.2] and 9.2 months [95% CI 7.8–11.9] for patients with ECOG 0 and ECOG >1, respectively [ref. ECOG >0, HR = 1.50, 95% CI 1.06–2.12, \( p = 0.024 \)]) (Fig. 2a), systemic inflammatory index (OS was 14.9 months [95% CI 11.8–17.9] and 12.7 months [95% CI 8.5–15.1] for patients with a low [<360] and high [>360] systemic inflammatory index, respectively [ref. >360, HR = 1.56, 95% CI 1.08–2.25, table]
Casadei-Gardini et al.: RAPID Index in Advanced Hepatocellular Carcinoma

p = 0.018]) (Fig. 2b), neutrophils (OS was 16.3 months [95% CI 12–18] and 11.2 months [95% CI 7–15] for patients with a low [<4,100] and high [>4,100] neutrophil count, respectively [ref. <4,100, HR = 0.59, 95% CI 0.40–0.89, p = 0.0118]) (Fig. 2c), platelets (OS was 17.9 months [95% CI 8.3–25.6] and 12.9 months [95% CI 10.8–15.6] for patients with a low [<100] and high [>100] platelet count, respectively [ref. > 100, HR = 0.63, 95% CI 0.41–0.97, p = 0.0373]) (Fig. 2d), AFP (OS was 14.7 months [95% CI 10.9–16.1] and 12.0 months [95% CI 8.0–15.8] for patients with a low [≤ 400] and high [>400] AFP level, respectively [ref. <400; HR = 0.64, 95% CI 0.41–0.98, p = 0.041]) (Fig. 2e), and AST (median OS was 24.3 months [95% CI 9–42] and 13.1 months [95% CI 9–16] for patients with a low [≤ 34] and high [>34] AST level, respectively [ref. <34, HR = 0.54, 95% CI 0.32–0.89, p = 0.004]) (Fig. 2f).

Following adjustment for clinical covariates (AFP, ECOG, AST, neutrophil, platelet, systemic inflammatory index, and RAPID index), multivariate analysis confirmed RAPID index ≤3,226 versus >3,226 (HR = 0.37, 95% CI 0.18–0.74, p = 0.0054), ECOG >0 versus 0 (HR = 1.92, 95% CI 1.25–2.96, p = 0.0028), and AST <34 versus >34 (HR = 0.40, 95% CI 0.20–0.80, p = 0.0095) as independent prognostic factors for OS (Table 2).

| Table 3. Patient characteristics between high and low RAPID index |
|---------------------------------------------------------------|
| <3,226 (24 patients) | >3,226 (135 patients) | p value |
|----------------------|-----------------------|---------|
| Median age (range), years | 68 (62–74) | 71 (66–71) | 0.97 |
| Etiology | | | |
| HCV | 12 (50%) | 62 (45.9%) | 0.91 |
| HBV | 5 (20.8%) | 33 (24.4%) | |
| Others | 7 (29.2%) | 40 (29.6%) | |
| BCLC stage | | | |
| B | 4 (16.7%) | 19 (14.1%) | 0.74 |
| C | 18 (75%) | 115 (85.2%) | |
| Unknown | 2 (8.3%) | 1 (0.7%) | |
| Child-Pugh | | | |
| A | 22 (91.6%) | 115 (85.2%) | |
| B | 1 (4.2%) | 9 (6.7%) | |
| Unknown | 1 (4.2%) | 11 (8.1%) | 1.00 |
| ECOG | | | |
| 0 | 9 (37.5%) | 73 (54.1%) | |
| Others | 13 (54.2%) | 60 (44.4%) | 0.25 |
| Unknown | 2 (8.3%) | 2 (1.5%) | |
| Extrahepatic disease | | | |
| No | 14 (58.3%) | 79 (58.5%) | |
| Yes | 8 (33.3%) | 55 (40.7%) | |
| Unknown | 2 (8.3%) | 1 (0.7%) | 0.81 |
| Portal vein thrombosis | | | |
| No | 11 (45.8%) | 78 (57.8%) | |
| Yes | 11 (45.8%) | 55 (40.7%) | |
| Unknown | 2 (8.3%) | 2 (1.5%) | 0.49 |
| Aspartate aminotransferase | | | |
| <34 | 2 (8.3%) | 17 (12.6%) | |
| >34 | 18 (75%) | 92 (68.1%) | |
| Unknown | 4 (16.7%) | 26 (19.3%) | 0.73 |
Fig. 2. Overall survival in relation to ECOG (a), systemic inflammatory index (SII) (b), neutrophils (c), platelets (d), AFP (e), and alanine transaminase (f).
Clinical Outcome in the Validation Cohort

In the validation cohort, the median OS was 26.9 months (95% CI 17.6–26.9) and 7.0 months (95% CI 6.2–9.2) for patients with a low (≤3,226) and high (>3,226) RAPID index, respectively (ref. <3,226, HR = 0.19, 95% CI 0.10–0.36, p < 0.0001) (Fig. 3).

Performing the same multivariate analysis of the training cohort (AFP, ECOG, AST, neutrophil, platelet, systemic inflammatory index, and RAPID index), the RAPID index (HR = 3.86, 95% CI 1.45–10.29, p = 0.007) was found to be an independent prognostic factor for OS (Table 4). The model had a C-index of 0.73.

Discussion

Our study on two independent cohorts (training and validation cohort) showed that the RAPID index is an independent predictor of OS for HCC patients treated with sorafenib. Indeed, our data highlighted that patients with a high RAPID index (>3,226) had a worse OS if compared with those with a low RAPID index (12 vs. 23 months). These results suggest that
the RAPID index might identify a small subset of patients who could significantly benefit from the treatment with sorafenib.

The RAPID index is composed of AFP, LDH, and NLR. The combination of these factors seems to be more precise and to have a stronger prognostic value as compared to each single component [17].

In fact, it seems that there is a greater energy if we assemble the qualities of the single elements: AFP as a tumor marker; neutrophils and lymphocytes representing the role of the immune system in favoring and preventing tumorigenesis; LDH as the inducer of hypoxic metabolism and the activator of carcinogenesis through HIF-1 alpha, a pro-oncogenic factor of a series of genes involved in the pathway of glycolytic metabolism, in angiogenesis, erythropoiesis, and cell survival [18].

In our study, a correlation between AFP and clinical outcomes was found, but this was not confirmed for NLR and LDH [19]. In our opinion, this difference depends on the study population. Patients enrolled in the two pivotal trials of sorafenib [1, 2] were more selected and with a lower rate of chronic liver disease if compared with our study population, which is more representative of the clinical practice. Patients with a severe hepatopathy have a different hematologic index if compared with those with mild liver disease; this may explain the lack of correlation between NLR and clinical outcomes.

Our data have also highlighted how AST and ECOG can predict the outcome in patients treated with sorafenib. AST values are probably increased because of the advanced stage of the disease; Berhane et al. [20] found that high AST values are common in patients with advanced HCC. Patient's performance status was pivotal for the prediction of response to therapy and the definition of outcome in patients affected by HCC treated with sorafenib. Dufour and colleagues [21] showed that ECOG performance status was predictive of survival in the same setting of patients.

The training and validation cohorts were different in terms of patient characteristics. We believe that this is the reason why we could not find a significant correlation between ECOG, AST, and clinical outcomes in the validation cohort.

The main strength of our study is that the analyses were performed on two independent cohorts of patients. The main limitation of this study was its retrospective nature; however, cases were consecutively selected, and this may have reduced potential bias. Thus, we were not able to collect all data of these patients (e.g., tumor size, clinical manifestations of hepatic dysfunction, CT scan, and comorbidities).

In conclusion, our investigation has identified a new index, based on simple and easily available hematochemical parameters, which can represent a novel useful tool to predict survival in HCC patients receiving sorafenib.

**Statement of Ethics**

The study protocol was reviewed and approved by the local Ethics Committee (CEIIAV: comitato etico IRST IRCCS AVR). Study number: IRST B041, protocol number; 5482/v.1, intern code: L3P1192. All patients provided written informed consent.

**Disclosure Statement**

The authors have no conflicts of interest to disclose. They did not receive financial support for this study.
Author Contributions

A.C.-G.: conception and design of the work; analysis and interpretation of data; review, drafting, and final approval of the manuscript.

All authors: acquisition, analysis and interpretation of data; review and final approval of the manuscript.

References

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul;359(4):378–90.
2. Cheng AL, Kang YK, Chen Z, Tao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25–34.
3. Marisi G, Cucchetti A, Ulii P, Canale M, Cabibbo G, Solaini L, et al. Ten years of sorafenib in hepatocellular carcinoma: are there any predictive and/or prognostic markers? World J Gastroenterol. 2018 Sep;24(36):4152–63.
4. Hu J, Wang N, Yang Y, Ma L, Han R, Zhang W, et al. Diagnostic value of alpha-fetoprotein combined with neutrophil-to-lymphocyte ratio for hepatocellular carcinoma. BMC Gastroenterol. 2010 Dec;10(1):106.
5. Faloppi L, ScartoZZi M, Bianconi M, Svegliati Baroni G, Toniutto P, Giampieri R, et al. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer. 2014 Feb;14(1):110.
6. Faloppi L, Bianconi M, Memeo R, Casadei Gardini A, Giampieri R, Bittoni A, et al. Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New. Biomed Res Int. 2016;2016:7196280.
7. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol. 2000;35(2):71–103.
8. Solaini L, Atmaja BT, Arumugam P, et al. The role of perioperative inflammatory-based prognostic systems in patients with colorectal liver metastases undergoing surgery. A cohort study. Int J Surg. 2016 Dec;36(PTA):8–12.
9. Casadei Gardini A, Foschi FG, Conti F, et al. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. Dig Liver Dis. 2019 May;51(5):681–88.
10. Casadei Gardini A, Marisi G, Canale M, Foschi FG, Donati G, Ercolani G, et al. Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival. OncoTargets Ther. 2018 Oct;11:6555–67.
11. Casadei Gardini A, Scarpelli E, Faloppi L, ScartoZZi M, Silvestris N, Santini D, et al. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget. 2016 Oct;7(41):67 142–9.
12. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol. 2011 May;54(5):948–55.
13. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013 Mar;31(7):860–7.
14. Kobayashi A, Hara H, Ohashi M, Nishimoto T, Yoshida K, Ohkohchi N, et al. Allogeneic MHC gene transfer enhances an effective antitumor immnity in the early period of autologous hematopoietic stem cell transplantation. Clin Cancer Res. 2007 Dec;13(24):7469–79.
15. Li Y, Zhang J. AURKA is a predictor of chemotherapy response and prognosis for patients with advanced squamous cell carcinoma. Tumour Biol. 2015 May;36(5):3577–64.
16. Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013 Jan;58(1):58–64.
17. Afshar M, Fletcher P, Bardoli AD, Ma YT, Punia P. Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort. Oncotarget. 2018 Mar;9(24):16988–95.
18. Yada M, Miyazaki M, Motomura K, Masumoto A, Nakamura M, Kojima M, et al. The prognostic role of lactate dehydrogenase serum levels in patients with hepatocellular carcinoma who are treated with sorafenib: the influence of liver fibrosis. J Gastrointest Oncol. 2016 Aug;7(4):615–23.
19. Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Santis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol. 2017 Nov;67(5):999–1008.
20. Berhane S, Fox R, Garcia-Fiñana M, Cucchetti A, Johnson P. Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment. Br J Cancer. 2019 Jul;121(2):117–24.
21. Gmürr A, Koly P, Knöpfli M, Dufour JF. FACT-Hep increases the accuracy of survival prediction in HCC patients when added to ECOG Performance Status. Liver Int. 2018 Aug;38(8):1468–74.